More Articles

Indian generics makers begin to dispatch remdesivir Generics/News | Posted 24/07/2020

Generic drugmakers Hetero and Cipla are among the first Indian manufacturers to dispatch a generic version of the investigational COVID-19 treatment remdesivir, which was originally developed by Gi...

US biosimilars pipeline for immunosuppressants, insulin and ophthalmology Reports | Posted 17/07/2020

Biologicals are becoming increasingly important in the pharmaceuticals market due to their use to treat previously intractable diseases. The global biological market is worth approximately US$276 b...

FDA approves Mylan’s adalimumab biosimilar Hulio Biosimilars/News | Posted 17/07/2020

The US Food and Drug Administration (FDA) has approved Mylan/Fujifilm’s adalimumab biosimilar Hulio (adalimumab-fkjp) on 7 July 2020. The product is the sixth adalimumab biosimilar to be approved b...

Quotas improve biosimilar use in Germany Biosimilars/Research | Posted 17/07/2020

An assessment of the role of cost control measures on biological drugs in Germany finds that quotas for biosimilars are in some cases associated with increased use and are overall more effective th...

New Zealand IBD charity releases position statement on biosimilars Biosimilars/General | Posted 17/07/2020

The charity Crohn’s and Colitis New Zealand has released a position statement on biosimilars, although there are not yet any biosimilars for inflammatory bowel disease (IBD) on the market in New Ze...

Generics applications under review by EMA – July 2020 Generics/General | Posted 17/07/2020

Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body [1]. Approval by EMA takes place by using a centrali...

EMA and HMA release joint network strategy to 2025 Guidelines | Posted 17/07/2020

The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have released a draft joint network strategy for the coming five years. A public consultation on the strategy will be open...

Cost savings from the use of generic Gleevec (imatinib) Generics/Research | Posted 17/07/2020

Modelling of the cost savings from the use of generic Gleevec (imatinib) in the US finds that US payers saved US$2.5 billion in years 1 and 2 following patent expiry. Projected savings in years 3 t...